Next week, CAMP4 VP of Platform Alla Sigova will present on our unique approach to amplifying RNA at the American Society of Gene & Cell Therapy’s 27th Annual Meeting. She’ll walk through how we applied our RAP Platform™ to develop our clinical candidate, CMP-CPS-001, for the potential treatment of urea cycle disorders. Mark your calendar: https://bit.ly/3UDBKX5 #ASGCT2024 #ASGCT #RNA #ureacycledisorders
CAMP4 Therapeutics’ Post
More Relevant Posts
-
Check out the new #QPS #podcast in conjunction with Bioanalysis Zone. Listen in to learn more about #genetherapy and #regulatoryaffairs implications.
Listen along to the ‘The new frontier’ podcast and discover the latest trends in the bioanalysis of cell and gene therapies! Featuring experts from QPS Holdings, LLC and Bristol-Myers Squibb, we’ll be delving into the DNA of CGTs in the field. Episode one is now live >>> https://hubs.ly/Q02mp9TN0
-
-
Looking forward to this discussion tomorrow at #ASGCT2024!
It’s not too late to join us for our symposium at the American Society of Gene & Cell Therapy’s 27th Annual Meeting tomorrow, May 8th. Join the Kriya team along with thought leaders for an engaging discussion surrounding #genetherapies and their potential as treatment options for millions of patients impacted by common diseases. Register here: https://bit.ly/3vYcv8r #ASGCT2024
-
-
Dear Network, I will be attending the American Society of Gene & Cell Therapy annual meeting in Baltimore and presenting a poster: Novel Animal Models to Evaluate Preclinical Studies of Thalassemia Thursday, May 9th, 12:00 PM Session Title: Genetic Disorders of the Blood and Immune System Final Abstract Number: 1160 Looking forward to meeting and connecting with you. Let me know if you're interested in setting up a time to chat. #asgct #asgct24 #cellandgenetherapy #celltherapy #mousemodels #preclinicalresearch #thalassemia
-
-
Is your bioproduction workflow "tool'ed up"? Book a meeting with me at #advancedtherapies week to find out when is the right time AND how to do it!
To celebrate the new year and coming together at Phacilitate Advanced Therapies Week, we are showcasing a new commercial video at BioLife Solutions booth 400. Engage our team with your bioproduction challenges to improve systems throughout your entire cell and gene therapy development process. Stop by the booth or watch the video now to “tool up your CGT bioproduction workflow.” #CGT #cellandgenetherapy #workflow #cellprocessing #ATW24
-
Dyno Therapeutics launches its second product, Dyno eCap1 for the eye today at ESGCT. Congrats to the team on yet another best-in-class capsid for the treatment of genetic disease and beyond. Better delivery=Better treatments. Key Data on Dyno eCap 1 Technology -- The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid. -- The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile. -- The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells. -- The Dyno eCap 1 vector was validated in cynomolgus monkey (Macaca fascicularis), the most relevant NHP model for predicting translatability to human clinical trials. Improved performance is highly consistent across bulk RNA-seq, single-cell RNA-seq and histology.
Today at #ESGCT2023 we were excited to announce the launch of our Dyno eCap™ 1 capsid, a field-leading AAV capsid for eye gene therapies 👁🧬. This vector transduces clinically-relevant cell types across the retina and outperforms both AAV2 and external engineered capsids in NHP experiments. Learn more about this breakthrough capsid at https://lnkd.in/eAeDC-vJ and contact bd@dynotx.com about licensing opportunities.
-
-
Dyno Therapeutics launches its second product, Dyno eCap1 for the eye today at ESGCT. Congrats to the team on yet another best-in-class capsid for the treatment of genetic disease and beyond. Better delivery=Better treatments. Key Data on Dyno eCap 1 Technology -- The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid. -- The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile. -- The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells. -- The Dyno eCap 1 vector was validated in cynomolgus monkey (Macaca fascicularis), the most relevant NHP model for predicting translatability to human clinical trials. Improved performance is highly consistent across bulk RNA-seq, single-cell RNA-seq and histology.
Today at #ESGCT2023 we were excited to announce the launch of our Dyno eCap™ 1 capsid, a field-leading AAV capsid for eye gene therapies 👁🧬. This vector transduces clinically-relevant cell types across the retina and outperforms both AAV2 and external engineered capsids in NHP experiments. Learn more about this breakthrough capsid at https://lnkd.in/eAeDC-vJ and contact bd@dynotx.com about licensing opportunities.
-
-
Check out three new, must-watch videos from ASGCT #PatientEducation! In Community Quick Takes: Informed Consent in Gene & Cell Therapy Research, we cover what an individual should know prior to giving their consent, and the role different stakeholders can play to improve this process. #genetherapy #celltherapy https://lnkd.in/e-hyyG5h
-
-
We were all beginners at one point. Register below to start your journey, or indeed enhance your knowledge...
🧬 Elevate your research with Single cell analysis! Join our 1-hour webinar to explore the potential of our Chromium Single Cell solutions. Discover regulatory gene relationships, investigate immune systems, and map epigenetic landscapes—and get the chance to win prizes!! Don't miss this opportunity to push the boundaries of your research. https://10xgen.com/3qi7tAz
-
-
If you are in Baltimore this week for #ASGCT2024, consider attending the "Clinical Translation of Gene and Cell Therapies" Education Session Wednesday, May 8 at 8am ET, where I will be discussing how gene-edited minipigs can expedite your path to the clinic. Also, be sure to stop by the Exemplar Genetics booth (#2059) and say "hi". #ASGCT #ExemplarGenetics
